Oil futures add to the previous day's losses as the market frets about the effect that U.S. trade tariffs could have on economic growth and oil demand. An unexpected 2.3 million barrel draw in U.S ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...

Wall Street is retreating from its record as a slide for Walmart weighs on U.S. stock indexes Thursday. The S&P 500 was down 0.6% in morning trading after setting all-time highs in each of the ...

Stock market today: Key stock indices closed slightly lower in volatile trading on Wednesday, with IT heavyweights leading the decline. The BSE Sensex settled at 75,939.18, down 28.21 points or 0. ...

Amid ongoing market downturn, as much as 15 stocks hit upper-circuit on Bombay Stock Exchange (BSE) on Tuesday's trading session. Indian benchmark indices ended nearly unchanged on Tuesday ...

Merck (NYSE:MRK) announced Tuesday that the European Commission approved its anti-cancer agent Welireg (belzutifan) as a treatment for two tumor conditions linked to kidneys. Accordingly, the oral ...

Palantir (NASDAQ: PLTR) stock posted another day of gains in Tuesday's trading. The software company's share price closed out the daily session up 4.6% and had been up as much as 4.9% earlier in ...

Gold, Silver Prices Today: Multi Commodity Exchange (MCX) gold price gained today i.e. February 18, 2025. MCX Gold for the April 4 contract opened at Rs 85,200 and touched an intraday high of Rs ...

The EC conditionally approved Merck’s Welireg for certain VHL disease-associated tumors and advanced RCC after two or more prior treatments. Approval is based on data from the LITESPARK-004 and ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. Gilead had the right to ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the “real culprit” for Merck shares remaining under ...